These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20882002)

  • 21. Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates.
    Verkerke HP; Williams JA; Guttman M; Simonich CA; Liang Y; Filipavicius M; Hu SL; Overbaugh J; Lee KK
    J Virol; 2016 Oct; 90(20):9471-82. PubMed ID: 27512064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.
    Schiffner T; de Val N; Russell RA; de Taeye SW; de la Peña AT; Ozorowski G; Kim HJ; Nieusma T; Brod F; Cupo A; Sanders RW; Moore JP; Ward AB; Sattentau QJ
    J Virol; 2016 Jan; 90(2):813-28. PubMed ID: 26512083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing.
    Humbert M; Rasmussen RA; Ong H; Kaiser FM; Hu SL; Ruprecht RM
    PLoS One; 2008; 3(12):e3937. PubMed ID: 19081789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.
    Derking R; Ozorowski G; Sliepen K; Yasmeen A; Cupo A; Torres JL; Julien JP; Lee JH; van Montfort T; de Taeye SW; Connors M; Burton DR; Wilson IA; Klasse PJ; Ward AB; Moore JP; Sanders RW
    PLoS Pathog; 2015 Mar; 11(3):e1004767. PubMed ID: 25807248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.
    de Taeye SW; Go EP; Sliepen K; de la Peña AT; Badal K; Medina-Ramírez M; Lee WH; Desaire H; Wilson IA; Moore JP; Ward AB; Sanders RW
    J Biol Chem; 2019 Apr; 294(14):5616-5631. PubMed ID: 30728245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Neutralizing Antibody Response to the HIV-1 Env Protein.
    Moore PL
    Curr HIV Res; 2018; 16(1):21-28. PubMed ID: 29173180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail.
    Samal S; Das S; Boliar S; Qureshi H; Shrivastava T; Kumar N; Goswami S; Bansal M; Chakrabarti BK
    Retrovirology; 2018 Jul; 15(1):50. PubMed ID: 30029604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.
    Kong L; Torrents de la Peña A; Deller MC; Garces F; Sliepen K; Hua Y; Stanfield RL; Sanders RW; Wilson IA
    Acta Crystallogr D Biol Crystallogr; 2015 Oct; 71(Pt 10):2099-108. PubMed ID: 26457433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.
    Prigent J; Jarossay A; Planchais C; Eden C; Dufloo J; Kök A; Lorin V; Vratskikh O; Couderc T; Bruel T; Schwartz O; Seaman MS; Ohlenschläger O; Dimitrov JD; Mouquet H
    Cell Rep; 2018 May; 23(9):2568-2581. PubMed ID: 29847789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
    Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
    Wu X
    Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.
    Wallace A; Stamatatos L
    J Virol; 2009 Aug; 83(16):7883-93. PubMed ID: 19494007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
    Antanasijevic A; Ueda G; Brouwer PJM; Copps J; Huang D; Allen JD; Cottrell CA; Yasmeen A; Sewall LM; Bontjer I; Ketas TJ; Turner HL; Berndsen ZT; Montefiori DC; Klasse PJ; Crispin M; Nemazee D; Moore JP; Sanders RW; King NP; Baker D; Ward AB
    PLoS Pathog; 2020 Aug; 16(8):e1008665. PubMed ID: 32780770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.
    Martinez-Murillo P; Tran K; Guenaga J; Lindgren G; Àdori M; Feng Y; Phad GE; Vázquez Bernat N; Bale S; Ingale J; Dubrovskaya V; O'Dell S; Pramanik L; Spångberg M; Corcoran M; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    Immunity; 2017 May; 46(5):804-817.e7. PubMed ID: 28514687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA.
    Jia M; Liberatore RA; Guo Y; Chan KW; Pan R; Lu H; Waltari E; Mittler E; Chandran K; Finzi A; Kaufmann DE; Seaman MS; Ho DD; Shapiro L; Sheng Z; Kong XP; Bieniasz PD; Wu X
    Cell Host Microbe; 2020 Jun; 27(6):963-975.e5. PubMed ID: 32315598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.